China is a region with a high prevalence of hepatitis B. According to incomplete statistics, there are at least 120 million people chronically infected with hepatitis B virus in China. Today, with the gradual increase of people’s health awareness, medical checkups for school admission and premarital examinations have exposed some asymptomatic infected people. For the sake of school admission and employment, many people infected with hepatitis B virus are desperate for treatment, especially for a good prescription for antiviral treatment. However, antiviral treatment for hepatitis B should not be used blindly. Some hepatitis B patients blindly believe in some advertisements in order to treat their disease. One patient was very anxious because he was found to be infected with the hepatitis B virus during a physical examination. He went to the hospital, and after the doctor’s examination, he was found to be a patient with normal liver function of hepatitis B “small triplet”. The doctor told him he didn’t need treatment. “How can we not treat it?” He sought medical help everywhere, blindly listened to the advertisements, spent nearly 20,000 yuan, not only did not make the hepatitis B virus clear, but also due to drug poisoning led to drug-related kidney damage. In fact, there are no drugs that can completely remove the hepatitis B virus with certain efficacy, and the few drugs that can suppress the virus only make the DNA of the virus negative, or transform the e antigen-positive “major triple-positive” state into the e antigen-negative “minor triple-positive” state. The “minor” form of hepatitis B virus infection is the “minor” form. If the liver function is normal and the HBVDNA is negative, it means that the infection is very small and the virus has not damaged the liver cells, which is what we call the “hibernation state” of the hepatitis B virus. There are a lot of hepatitis B virus carriers in China, and less than 1/3 of these “hibernating” “little three yang” infected people will, for one reason or another, have an attack of liver disease, and most infected people can live a healthy life. If you blindly believe in advertising and use drugs, not only will you not be able to cure your liver disease, but sometimes there may be adverse reactions that can cause disease in other organs, and sometimes even activate the “hibernating” virus, causing abnormal liver function. Some patients see a report of anti-hepatitis B drugs tested on genetically modified rats and think that the drug must be able to cure hepatitis B. They ask around about this gene therapy. Some false advertising is much faster than scientific research, and in the blink of an eye “GMO therapy” has become fashionable. In fact, animal testing is still far from a cure for human disease! An effective antiviral drug has to go through preclinical (animal), phase I (healthy people and a few patients), phase II and phase III (international multicenter, double-blind control) clinical studies in accordance with the international unified GCP standards before it can be officially marketed, and some drugs have to go through phase IV clinical studies. In these trials, not only the effectiveness of the drug is observed, but also its safety. Before the end of these trials, no one can determine whether it can be safely and effectively used in the clinic, and sometimes may be halfway. For example, the nucleoside anti-hepatitis B virus drug Lobucavir (lobucavir) studied in foreign countries in previous years was found to cause squamous epithelial cancer in the late stage of the trial, so clinical trials have been stopped. This process, at least 2 to 3 years, can not be a few days of work from the mice used in patients. The right drug but not the right treatment is also considered blind treatment to see some effective anti-hepatitis B virus drugs in recent years, some hepatitis B virus infection of normal liver function in order to achieve the effect of clearing the hepatitis B virus, regardless of its applicability, blindly purchase their own drugs for treatment. Although these patients can achieve a negative HBVDNA result at the beginning of treatment, it will still be elevated again after stopping the medication, and the result will eventually lead to the development of virus resistance, and even make it impossible to choose an effective treatment drug when antiviral treatment is really needed later. In fact, antiviral drugs for hepatitis B are prescription drugs, and their best indication is for patients with HBVDNA-positive chronic active hepatitis with repeated fluctuations in ALT between 100 and 300 units; they can also be used for patients with cirrhosis who have active hepatitis B virus replication, liver and kidney transplantation and hepatitis B infection during chemotherapy and perioperative period of tumor. This is due to the fact that we have confirmed at the time of clinical studies before the drugs were marketed that these drugs are more effective in patients with abnormal liver function and less effective in patients with normal liver function. It can only serve to inhibit hepatitis B virus replication and cannot clear the hepatitis B virus. In addition, because the effects of some new nucleoside antiviral drugs on the fetus are not fully known, they should not be used in early pregnancy; interferon has a certain effect on thyroid function and also has a suppressive effect on blood picture, and should also be used with caution in patients with hepatitis B who have thyroid disorders and low white blood cells. The doctor should also fully understand the patient’s past medical history and general condition before treatment, and conduct appropriate tests to determine whether antiviral treatment is needed. People’s living standards have improved, health awareness has increased, there is a disease to be treated, but the treatment also needs to reduce a little blindness. In other words: to cure the disease, don’t spend money in vain, and don’t spend money in vain not to cure the disease and add disease!